Acalabrutinib vs Ibrutinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Mantle Cell Lymphoma
Shared mechanism: BTK · full Mantle Cell Lymphoma pipeline
Acalabrutinib
Marketed by AstraZeneca
NCT02213926 · Phase 2 · active, not recruiting
This was a single-arm, open-label study without randomization, blinding, or a comparator. Although the clinical response endpoint was reported in 124 participants, a comparative treatment effect could not be tested, so the evidence is limited.
Next expected readout: December 2026 · NCT04115631 (registry estimate)
Reported efficacy
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants (not_applicable)
Result source: NCT02213926
Ibrutinib
Marketed by AbbVie and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT01479842 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Mantle Cell Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Ibrutinib: registry results are on file for Mantle Cell Lymphoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Chronic Lymphocytic Leukemia
Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline
Acalabrutinib
Marketed by AstraZeneca
NCT02475681 · Phase 3 · completed
This was a randomized phase 3 trial of 535 people with an active comparator and a hard progression-free survival endpoint that was clearly met. Only outcome assessors were masked and treatment was open-label, so it is graded below the highest tier.
Next expected readout: December 2026 · NCT05971251 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) (met)
Result source: NCT02477696
Ibrutinib
Marketed by AbbVie and partners
NCT01578707 · Phase 3 · completed
This was a large randomized, active-controlled trial of ibrutinib versus ofatumumab, with progression-free survival as a clinical primary endpoint and a statistically significant favorable result for ibrutinib. However, treatment was open-label rather than double-blinded, so the evidence is graded moderate despite the strong primary result.
Next expected readout: December 2026 · NCT03513562 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (Up to 5 years): Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) (met)
Result source: NCT01611090
Results for Chronic Lymphocytic Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Acalabrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acalabrutinib's landscape · Ibrutinib's landscape